MicroPort^® NeuroTech Completes Strategic Financing with Shareholder Structure Optimization, as Foundation for Next-Step Global Expansion

Shanghai, China, 11 November 2021 - MicroPort NeuroTech Limited (MicroPort® NeuroTech), a subsidiary of MicroPort Scientific Corporation (MicroPort®) that focusses on the development and promotion of innovative therapeutic solutions for cerebrovascular diseases, successfully entered a financing agreement of US$ 150 million in amount as planned, which brought to NeuroTech several renowned strategic investors including CICC Capital, HHF Capital, Broad Vision Funds, Runkun Partners and Prosperous Alliance. Meanwhile, Biolink Capital, which subscribed for US$70 million convertible bonds of NeuroTech in 2020, had its bond converted and made a follow-up investment.

Mr. Yiqun Wang, Executive Vice President and Director of Engineering Technology Center of MicroPort® NeuroTech stated, “Having been seeking development in the neurointerventional medical device industry for many years, NeuroTech has now become a total stroke solution provider with a global footprint. We have laid solid foundation for independent R&D and product commercialization. The entry of strategic partners during this round of financing is expected to provide more resources for our future R&D, production and industrial expansion. We are also confident that they will bring more vitality and possibilities for our future development.”

Founded in 2012, MicroPort® NeuroTech is one of the first medical device companies in China to enter the field of neurointervention. To date, it has independently developed and commercialized 8 Class III medical devices in the field of neurointervention, including APOLLO™ Intracranial Stent System (the world's first intracranial graft covered stent system), WILLIS® Intracranial Stent Graft System, and the first blood flow diverter in China Tubridge® Vascular Reconstruction Device. The company owns the most complete line of stroke intervention products in China.

After nearly 10 years of development, MicroPort® NeuroTech has built a talented team that is highly responsive to clinical needs and strong in innovation and R&D. MicroPort® NeuroTech owns more than 100 domestic and international patents, and has been awarded recognitions by Shanghai municipal government as a Pilot Company for Patent Development, a Specialized and Technically Advanced Company of the city, a Science and Technology Giant in Shanghai, and an Exemplary Company of Brand Cultivation in Shanghai. It has also successfully passed evaluation to be classified as a high-tech company.

Mr. Zhiyong Xie, President of MicroPort® NeuroTech, noted, “Globally, stroke is the second biggest cause of death, only next to cardiovascular diseases, and China has the highest incidence of stroke in the world. Over the past 30 years, the incidence of stroke in China has risen dramatically and younger patients have fallen victim to this illness. With accelerated progress of building stroke treatment centers in China, urgent demands are increasing for greater variety of neurointerventional products. MicroPort® NeuroTech will continue to broaden and deepen its product lines and form a systematic plan around hemorrhagic, ischemic, and accessory products to address the unmet clinical needs and provide more accessible medical solutions for patients of cerebrovascular diseases worldwide.”

After nearly 10 years of development, MicroPort® NeuroTech has built a talented team that is highly responsive to clinical needs and strong in innovation and R&D. MicroPort® NeuroTech owns more than 100 domestic and international patents, and has been awarded recognitions by Shanghai municipal government as a Pilot Company for Patent Development, a Specialized and Technically Advanced Company of the city, a Science and Technology Giant in Shanghai, and an Exemplary Company of Brand Cultivation in Shanghai. It has also successfully passed evaluation to be classified as a high-tech company.

Mr. Bo Peng, Chairman of MicroPort® Greater China Executive Committee, Chief Marketing Officer, and Chairman of MicroPort® NeuroTech, commented, “This round of financing brought several renowned strategic investors that will lead to a modern shareholder structure and professional corporate governance for MicroPort® NeuroTech, while maintaining independent operation. We will work together with our investors to promote the development of the neurointerventional industry.”